[1]王英英,朱　娇.三阴性乳腺癌患者血清miR-146a，miRlet-7a水平表达与临床病理特征和化疗疗效的相关性研究[J].现代检验医学杂志,2021,36(06):60-63.[doi:10.3969/j.issn.1671-7414.2021.06.012]
　WANG Ying-ying,ZHU Jiao.Correlation of Serum miR-146a and miR let-7a Expression with Clinicopathological Characteristics and Chemotherapy Efficacy in Patients with Triple Negative Breast Cancer[J].Journal of Modern Laboratory Medicine,2021,36(06):60-63.[doi:10.3969/j.issn.1671-7414.2021.06.012]
点击复制

三阴性乳腺癌患者血清miR-146a，miRlet-7a水平表达与临床病理特征和化疗疗效的相关性研究()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第36卷
期数:
2021年06期
页码:
60-63
栏目:
论　著
出版日期:
2021-12-15

文章信息/Info

Title:
Correlation of Serum miR-146a and miR let-7a Expression with Clinicopathological Characteristics and Chemotherapy Efficacy in Patients with Triple Negative Breast Cancer
文章编号:
1671-7414（2021）06-060-04
作者:
王英英; 朱　娇
（1.陕西中医药大学附属医院肿瘤二科，陕西咸阳 712000；2.兵器工业五二一医院肿瘤血液病科，西安 710065）
Author(s):
WANG Ying-ying;  ZHU Jiao
（1. the Second Oncology Department, Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine,Shaanxi Xianyang 712000, China; 2. Department of Oncology Hematology, 521 Hospital of Norinco Group, Xi’an 710065, China）
关键词:
三阴性乳腺癌; miR-146a; miR let-7a; 临床病理特征
分类号:
R737.9；R730.43
DOI:
10.3969/j.issn.1671-7414.2021.06.012
文献标志码:
A
摘要:
目的　探究三阴性乳腺癌(triple negative breast cancer, TNBC)患者血清miR-146a和miR let-7a水平表达与临床病理特征和化疗疗效的相关性。方法　选择陕西中医药大学附属医院2014年7月～2016年6月行乳腺癌根治术并经免疫组化(immunohistochemical, IHC)检测证实为TNBC的79例患者为研究对象。采用实时荧光定量PCR(quantitative real-time PCR, qRT-PCR)检测血清miR-146a和miR let-7a的水平。相关性采用Spearman秩相关分析。结果　血清miR-146a和miR let-7a在肿瘤直径≥3 cm，临床分期III期和淋巴结转移的患者中的表达水平高于肿瘤直径＜3 cm者，临床分期I~II期和无淋巴结转移的患者，差异具有统计学意义(t=7.41~10.39，均P＜0.05)。TNBC患者化疗后血清miR-146a和miR let-7a表达水平(0.81±0.32和0.60±0.26)显著低于化疗前(1.77±0.51和1.92±0.77)，差异具有统计学意义(t=11.31，10.11，均P=0.00)。疾病控制组患者血清miR-146a和miR let-7a表达水平(0.37±0.12和0.51±0.17)低于疾病进展组(1.40±0.79和1.62±0.55)，差异具有统计学意义(t=8.97，10.22，均P＜0.05)。Spearman秩相关分析显示血清miR-146a和miR let-7a表达水平与化疗疗效呈负相关(r=-0.199，-0.150，均P＜0.01)。结论　血清miR-146a和miR let-7a表达水平与肿瘤直径、临床分期、淋巴结转移和化疗疗效相关。
Abstract:
Objective　To explore the correlation between serum miR-146a and miR let-7a expression and clinicopathological characteristics and chemotherapy efficacy in patients with triple negative breast cancer (TNBC). Methods　Seventy-nine patients with TNBC who underwent radical mastectomy of breast cancer and were confirmed by immunohistochemical (IHC) detection in the Affiliated Hospital of Shaanxi University of traditional Chinese Medicine from July 2014 to June 2016 were selected as the research subjects. Quantitative real-time PCR(qRT-PCR) was used to detect the levels of serum miR-146a and miR let-7a. Spearman rank correlation analysis was used for correlation analysis. Results　The expression level of serum miR-146a and miR let-7a in patients with tumor diameter≥3 cm, clinical stage III and lymph node metastasis was higher than that in patients with tumor diameter<3 cm, clinical stage I~II and no lymph node metastasis, and the difference were statistically significant (t=7.41~10.39, all P<0.05). The expression levels of serum miR-146a and miR let-7a in TNBC patients after chemotherapy (0.81±0.32 and 0.60±0.26) were significantly lower than those before chemotherapy (1.77±0.51 and 1.92±0.77), and the difference was statistically significant (t=11.31, 10.11, all P=0.00). The expression levels of serum miR-146a and miR let-7a in the disease control group (0.37±0.12 and 0.51±0.17) were lower than those in the disease progression group (1.40±0.79 and 1.62±0.55), and the difference was statistically significant (t=8.97, 10.22, all P<0.05). Spearman rank correlation analysis showed that the expression levels of serum miR-146a and miR let-7a were negatively correlated with chemotherapy efficacy (r= -0.199, -0.150, all P<0.01). Conclusion　The expression levels of serum miR-146a and miR let-7a were correlated with tumor diameter, clinical stage, lymph node metastasis and chemotherapy efficacy.

参考文献/References:

[1] 张继博, 史业辉, 贾勇圣, 等. 三阴性乳腺癌治疗进展[J]. 肿瘤,2017, 37(7):788-794.ZHANG Jibo, SHI Yehui, JIA Yongsheng, et al.Advances in treatment of triple negative breast cancer[J]. Tumor, 2017, 37(7):788-794.
[2] 倪晨，李婷，吴振华，等．三阴性乳腺癌化疗进展[J].中国癌症杂志，2014, 24(4):316-320.NI Chen, LI Ting, WU Zhenhua, et al. Progress onchemotherapy for triple negative breast cancer [J].China Oncology, 2014, 24(4):316-320.
[3] 王舒淇，王东生．microRNA 在三阴性乳腺癌转移中的作用[J]．国际检验医学杂志,2020,41(13):1640-1644．WANG Shuqi, WANG Dongsheng. Role of microRNAin triple negative breast cancer metastasis [J].International Journal of Laboratory Medicine, 2020,41(13):1640-1644.
[4] 万军. 血清肿瘤标志物CA153,CA125,CEA 和HER-2 联合检测在乳腺癌诊断中的价值[J]. 现代检验医学杂志,2018,33(6):119-121.WAN Jun. Value of combined detection of tumormarkers CA153,CA125,CEA and HER-2 in thediagnosis of breast cancer [J]. Journal of ModernLaboratory Medicine,2018,33(6):119-121.
[5] 杨永德，周焱琳．浸润性乳腺癌组织中miRNA-206表达与临床病理及预后的关系[J]．现代检验医学杂志,2019,34(4):45-48.YANG Yongde, ZHOU Yanlin. Relationship betweenexpression of miRNA-206 and clinical pathologyand prognosis in invasive breast cancer[J]. Journal ofModern Laboratory Medicine, 2019, 34(4):45-48.
[6] 袁中玉, 王树森, 高岩, 等.305 例三阴乳腺癌患者的临床特征及预后因素分析[J]. 癌症,2008，27(6):561-565.YUAN Zhongyu, WANG Shusen, GAO Yan, et al.Clinical characteristics and prognosis of triple-negativebreast cancer:a report of 305 cases [J] . Chinese Journalof Cancer, 2008,27(6):561-565.
[7] 何姝槿，陈厚文，熊丽霞．MicroRNA 对EMT 的调节作用及其与肿瘤侵袭的关系[J]．中国生物化学与分子生物学报，2016, 32(11): 1197-1205.HE Shujin, CHEN Houwen, XIONG Lixia. Effects ofmicroRNA on tumor epithelial-mesenchymal transition[J]. Chinese Journal of Biochemistry and MolecularBiology, 2016, 32(11): 1197-1205.
[8] 曾长青, 黄良祥, 郑羽, 等.miR-146a 在结肠癌中的表达及意义[J]. 南方医科大学学报, 2014, 34(3):396-400.ZENG Changqing, HUANG Liangxiang, ZHENG Yu,et al. Expression of miR-146a in colon cancer and itssignificance [J].Journal of Southern Medical University,2014, 34 (3): 396-400.
[9] 谭俊龙, 郑明霞, 刘湘宁, 等.miR-146a 的功能及其靶基因的研究进展[J]. 生命科学,2019,32(4):387-395.TAN Junlong, ZHENG Mingxia, LIU Xiangning, et al.Advances in the function and target genes of miR-146a [J].Chinese Bulletin of Life Sciences, 2019,32(4):387-395.
[10] 李封，张艳，张琼，等. 外泌体介导的Let-7a 通过下调MYC 表达抑制三阴性乳腺癌细胞的恶性生物学行为[J]. 中国肿瘤生物治疗杂志，2019, 26(9)：962-968.LI Feng，ZHANG Yan，ZHANG Qiong，et al.Exosome-mediated Let-7a in hibits malignant biologicalbehaviors of triple-nega-tive breast cancer cells bydown-regulating MYC expression[J].Chinese Journalof Cancer Biotherapy,2019,26(9):962-968.

相似文献/References:

[1]肖姗姗,李 越,周艳阳,等.基于TCGA 数据库构建三阴性乳腺癌预后相关的ceRNA 调控网络及分析[J].现代检验医学杂志,2023,38(01):83.[doi:10.3969/j.issn.1671-7414.2023.01.016]
　XIAO Shan-shan,LI Yue,ZHOU Yan-yang,et al.Construction and Analysis of ceRNA Regulatory Network Related to Prognosis of Triple Negative Breast Cancer Based on TCGA Database[J].Journal of Modern Laboratory Medicine,2023,38(06):83.[doi:10.3969/j.issn.1671-7414.2023.01.016]

备注/Memo

备注/Memo:
作者简介：王英英（1986-），女，硕士，主治医师，研究方向：常见肿瘤的诊疗，E-mail:listars555@163.com。通讯作者：朱娇（1987-），女，硕士，主治医师，研究方向：肿瘤血液病的临床诊疗，E-mail:aa362484318@126.com。
更新日期/Last Update: 1900-01-01